Theravance Biopharma, Inc. (NASDAQ:TBPH) has received an average rating of “Hold” from the nine analysts that are covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $45.20.

Several equities research analysts recently commented on TBPH shares. Zacks Investment Research upgraded Theravance Biopharma from a “sell” rating to a “hold” rating in a report on Tuesday, September 5th. ValuEngine downgraded Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Cantor Fitzgerald reiterated a “buy” rating and issued a $55.00 price objective on shares of Theravance Biopharma in a report on Tuesday, September 26th. BidaskClub downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Sunday, July 16th. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Theravance Biopharma in a report on Wednesday, August 2nd.

ILLEGAL ACTIVITY NOTICE: “Theravance Biopharma, Inc. (TBPH) Given Average Recommendation of “Hold” by Analysts” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/11/01/theravance-biopharma-inc-tbph-given-average-recommendation-of-hold-by-analysts.html.

Theravance Biopharma (NASDAQ:TBPH) opened at 28.86 on Wednesday. The company has a 50 day moving average of $32.83 and a 200-day moving average of $35.05. Theravance Biopharma has a one year low of $23.15 and a one year high of $43.44. The stock’s market capitalization is $1.55 billion.

In other news, Director Henrietta Fore purchased 6,000 shares of the business’s stock in a transaction on Friday, August 11th. The stock was acquired at an average cost of $23.99 per share, for a total transaction of $143,940.00. Following the purchase, the director now directly owns 24,000 shares in the company, valued at approximately $575,760. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Bradford J. Shafer sold 14,670 shares of the business’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $30.77, for a total value of $451,395.90. Following the sale, the executive vice president now owns 134,327 shares of the company’s stock, valued at $4,133,241.79. The disclosure for this sale can be found here. Insiders purchased a total of 20,000 shares of company stock valued at $494,300 over the last quarter. 6.10% of the stock is owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. grew its stake in shares of Theravance Biopharma by 3.6% during the 2nd quarter. BlackRock Inc. now owns 3,638,838 shares of the biopharmaceutical company’s stock valued at $144,972,000 after purchasing an additional 126,393 shares during the period. Vanguard Group Inc. grew its stake in shares of Theravance Biopharma by 3.8% during the 2nd quarter. Vanguard Group Inc. now owns 3,197,277 shares of the biopharmaceutical company’s stock valued at $127,379,000 after purchasing an additional 116,981 shares during the period. State Street Corp grew its stake in shares of Theravance Biopharma by 2.2% during the 2nd quarter. State Street Corp now owns 889,682 shares of the biopharmaceutical company’s stock valued at $35,443,000 after purchasing an additional 19,428 shares during the period. Northern Trust Corp grew its stake in shares of Theravance Biopharma by 6.1% during the 2nd quarter. Northern Trust Corp now owns 530,049 shares of the biopharmaceutical company’s stock valued at $21,117,000 after purchasing an additional 30,611 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Theravance Biopharma by 5.8% during the 1st quarter. Geode Capital Management LLC now owns 330,280 shares of the biopharmaceutical company’s stock valued at $12,160,000 after purchasing an additional 18,177 shares during the period. Institutional investors and hedge funds own 84.86% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.